Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Celcuity Inc.NASDAQ: CELC

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$47K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$11.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$167K— YoY
LTMJun 2026
-$47K-33.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(167K) USD
Year-over-year change
—

Gross Profit vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's LTM Jun 2026 gross profit of -$47K is the lowest of the 6 companies compared; the peer median is $261.97M.
  • Its year-over-year change of -33.3% is the 5th highest of 6, against a peer median of +8.7%.
CELC Competitors Peer median
Gross Profit for CELC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NEONeoGenomics, Inc.LTM Jun 2026$328.9M +8.7%+14.6%42.9%
BLLNBillionToOne, Inc.LTM Jun 2026$283.22M +122.4%—71.3%
CSTLCastle Biosciences, Inc.LTM Mar 2026$261.97M -7.9%+37.5%77.1%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$232.4M +71.5%+17.3%75.4%
PSNLPersonalis, Inc.LTM Mar 2026$8.85M -69.0%—13.7%
CELCCelcuity Inc.LTM Jun 2026-$47K -33.3%——
Peer median (excluding CELC) $261.97M+8.7%+17.3%71.3%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000167K
Gross Profit0000(167K)
Gross Margin—————
Research & Development25.76M35.29M60.59M104.2M145M
Selling, General & Admin2.6M4.38M5.64M9.06M27.2M
Operating Expenses28.36M39.39M66.23M113.27M172.19M
Depreciation & Amortization303.24K210.92K142.77K129.95K167K
EBITDA(28.04M)(38.05M)(58.31M)(101.37M)(159.73M)
EBITDA Margin—————
Operating Income(28.36M)(39.39M)(66.23M)(113.27M)(172.19M)
Operating Margin—————
Interest Income13.26K1.13M7.78M11.77M12.3M
Interest Expense1.26M2.11M5.33M10.28M17.15M
Other Income / Expenses(1.25M)(978.95K)2.45M1.49M(4.85M)
Income Before Tax(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Net Margin—————
EPS (Basic)(2.28)(2.68)(2.69)(2.83)(3.78)
EPS (Diluted)(2.28)(2.68)(2.69)(2.83)(3.78)
Weighted Avg Shares13.38M15.42M23.68M39.45M52.54M
Weighted Avg Shares (Diluted)13.38M15.42M23.68M39.45M52.54M

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.